Immatics N.V. — Regulatory Filings 2021

May 11, 2021

6-K 1 dp150794_6k.htm FORM 6-K Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

May 11, 2021

Commission File Number: 001-39363

IMMATICS N.V.

Paul-Ehrlich-Straße 15

72076 Tübingen, Federal Republic of Germany

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Field: Rule-Page

Field: /Rule-Page Field: Page; Sequence: 1

Field: /Page

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On May 11, 2021, Immatics N.V. (the “Company”) issued a press release announcing preclinical proof-of-concept data for its product candidate IMA402. A copy the press release is attached hereto as Exhibit 99.1.

On May 11, 2021, the Company made available a presentation relating to its TCER programs on its website. A copy the presentation is attached hereto as Exhibit 99.2. The fact that this presentation is being made available and filed herewith is not an admission as to the materiality of any information contained in the presentation. The information contained in the presentation is being provided as of May 11, 2021 and the Company does not undertake any obligation to update the presentation in the future or to update forward-looking statements to reflect subsequent actual results.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release dated May 11, 2021
99.2	Presentation dated May 11, 2021

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 11, 2021
By:	/s/ Harpreet Singh
Name:	Harpreet Singh
Title:	Chief Executive Officer

Field: Page; Sequence: 2; Options: Last

Field: /Page